RE:RE:RE:RE:RE:RE:This constant selling........... Clarify what the breadth/meaning of 'Commercial Revenues' entails
Starting Jan 2023 Negotiation Mid-End 2022 for to be realized as Commercial Revenue Jan 2023?
1. A buyout of 'Developed IP technology' TLD-1433 + ACT for NMIBC and Rights to MIBC
2. FDA actually speeds us along with BTD and AA... and we actually get our valuation.
Both would suprise me..
Missing both and sharking the shareholders with another PP would be par for the course..
Endocyte had a 10 month negotiation that took their stock from $12 to $24 dollars before the final number was settled on
1b valuation at $12 turned into 2b at $24.
So that means... If Roger starts negotiations..... we're not a .30c stock
Can we please stop f'ing around here and pretending......
the AGM is a big moment 3 years since the 2019 PP.... and I want to know why we're not at $2 bucks
ScienceFirst wrote:
TLT has identified commercial revenues (projected) starting Jan. 2023. So I assume they have more info and insights than you.
_____________________
LaserStock29 - (5/27/2022 9:25:50 AM)
RE:RE:RE:RE:This constant selling...........
Ya if we apply Q4 2022 for BTD and that takes 6 months.. then AA takes what 4months. Your basically end of 2023 Thanks but no thanks. That won't fly at the agm A buyout of technologies is very much a reasonable position at this point And we know pharma influences fda in decision making aka the vaccine right. So if a big pharma paid roger u know they Seinfeld the hammer to get It the rest of the way I'm absolutely sick of Thomas the blue trail little east york stories of Roger's baby has to grind it out at .30c Endocyte deal is the pinnacle template for a single asset The range for deals is 2-10b. And I didn't say for all of the IP lol